These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27847272)

  • 21. Structures of complexes of type 5 17β-hydroxysteroid dehydrogenase with structurally diverse inhibitors: insights into the conformational changes upon inhibitor binding.
    Amano Y; Yamaguchi T; Niimi T; Sakashita H
    Acta Crystallogr D Biol Crystallogr; 2015 Apr; 71(Pt 4):918-27. PubMed ID: 25849402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).
    Flanagan JU; Atwell GJ; Heinrich DM; Brooke DG; Silva S; Rigoreau LJ; Trivier E; Turnbull AP; Raynham T; Jamieson SM; Denny WA
    Bioorg Med Chem; 2014 Feb; 22(3):967-77. PubMed ID: 24411201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pentafluorosulfanyl-containing flufenamic acid analogs: Syntheses, properties and biological activities.
    Hendriks CM; Penning TM; Zang T; Wiemuth D; Gründer S; Sanhueza IA; Schoenebeck F; Bolm C
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4437-40. PubMed ID: 26372652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
    Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
    Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
    He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
    J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors.
    Sun M; Zhou Y; Zhuo X; Wang S; Jiang S; Peng Z; Kang K; Zheng X; Sun M
    Chem Biodivers; 2020 Dec; 17(12):e2000519. PubMed ID: 33111427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer.
    Pippione AC; Kovachka S; Vigato C; Bertarini L; Mannella I; Sainas S; Rolando B; Denasio E; Piercy-Mycock H; Romalho L; Salladini E; Adinolfi S; Zonari D; Peraldo-Neia C; Chiorino G; Passoni A; Mirza OA; Frydenvang K; Pors K; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
    Eur J Med Chem; 2024 Mar; 268():116193. PubMed ID: 38364714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
    Jamieson SM; Gu Y; Manesh DM; El-Hoss J; Jing D; Mackenzie KL; Guise CP; Foehrenbacher A; Pullen SM; Benito J; Smaill JB; Patterson AV; Mulaw MA; Konopleva M; Bohlander SK; Lock RB; Wilson WR
    Biochem Pharmacol; 2014 Mar; 88(1):36-45. PubMed ID: 24434189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
    Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.
    Wangtrakuldee P; Adeniji AO; Zang T; Duan L; Khatri B; Twenter BM; Estrada MA; Higgins TF; Winkler JD; Penning TM
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105283. PubMed ID: 30641225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library.
    Brožič P; Turk S; Adeniji AO; Konc J; Janežič D; Penning TM; Lanišnik Rižner T; Gobec S
    J Med Chem; 2012 Sep; 55(17):7417-24. PubMed ID: 22881866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
    Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
    J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
    Gobec S; Brozic P; Rizner TL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer.
    Liu Y; Chen Y; Jiang J; Chu X; Guo Q; Zhao L; Feng F; Liu W; Zhang X; He S; Yang P; Fang P; Sun H
    Eur J Med Chem; 2023 Feb; 247():115013. PubMed ID: 36566714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.